Literature DB >> 15777188

Pancreatic amylin as a centrally acting satiating hormone.

Thomas A Lutz1.   

Abstract

This review summarizes the present knowledge concerning the anorectic action of the pancreatic hormone amylin. It focuses mainly on the role of amylin as a short term satiating peptide. Since there is some evidence however that basal amylin levels might play a role in the long term control of food intake and/or body weight, this aspect will be discussed briefly towards the end of this review. Concerning amylin as a satiating hormone, it is well established that amylin is released during meals, and that exogenous amylin leads to a dose-related reduction in meal size. Amylin has a rapid onset and brief duration of action. The area postrema (AP) plays a predominant role in peripheral amylin's satiating effect, involving a direct activation of AP neurons by blood-borne amylin. The nucleus of the solitary tract (NTS) relays this effect to higher brain structures, the lateral parabrachial nucleus, and possibly the central nucleus of the amygdala and the bed nucleus of the stria terminalis. Amylin's anorectic effect may in part be due to reduced expression of orexigenic neuropeptides in the lateral hypothalamic area. The anorectic action of amylin is one important factor in amylin's overall role to control the influx of nutrients into the circulation. By reducing food intake, gastric acid secretion, limiting the rate of gastric emptying and diminishing pancreatic glucagon and digestive enzyme secretion, amylin regulates nutrient appearance and postprandial glucose concentration. Amylin seems to be a necessary and complementary factor to insulin, which regulates the rate of nutrient disappearance. In this sense, amylin and insulin are adjunct players in the control of nutrient fluxes, and amylin's role to control feeding is a pivotal factor in this regard.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15777188     DOI: 10.2174/1389450053174596

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  28 in total

Review 1.  Role of gastrointestinal hormones in feeding behavior and obesity treatment.

Authors:  Timothy Sean Kairupan; Haruka Amitani; Kai-Chun Cheng; Joshua Runtuwene; Akihiro Asakawa; Akio Inui
Journal:  J Gastroenterol       Date:  2015-09-07       Impact factor: 7.527

Review 2.  Potential use of exenatide for the treatment of obesity.

Authors:  Franco Folli; Rodolfo Guardado Mendoza
Journal:  Expert Opin Investig Drugs       Date:  2011-10-24       Impact factor: 6.206

Review 3.  Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Authors:  Stephen C Woods; Thomas A Lutz; Nori Geary; Wolfgang Langhans
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 4.  Modulation of appetite by gonadal steroid hormones.

Authors:  Lori Asarian; Nori Geary
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 5.  Disordered eating behavior in individuals with diabetes: importance of context, evaluation, and classification.

Authors:  Deborah L Young-Hyman; Catherine L Davis
Journal:  Diabetes Care       Date:  2010-03       Impact factor: 17.152

Review 6.  Changes in neurohormonal gut peptides following bariatric surgery.

Authors:  C N Ochner; C Gibson; M Shanik; V Goel; A Geliebter
Journal:  Int J Obes (Lond)       Date:  2010-07-13       Impact factor: 5.095

Review 7.  Amylin-mediated control of glycemia, energy balance, and cognition.

Authors:  Elizabeth G Mietlicki-Baase
Journal:  Physiol Behav       Date:  2016-02-27

8.  Examination of Psychosocial and Physiological Risk for Bulimic Symptoms in Youth With Type 1 Diabetes Transitioning to an Insulin Pump: A Pilot Study.

Authors:  Claire M Peterson; Deborah Young-Hyman; Sarah Fischer; Jessica T Markowitz; Andrew B Muir; Lori M Laffel
Journal:  J Pediatr Psychol       Date:  2018-01-01

9.  Amylin modulates the mesolimbic dopamine system to control energy balance.

Authors:  Elizabeth G Mietlicki-Baase; David J Reiner; Jackson J Cone; Diana R Olivos; Lauren E McGrath; Derek J Zimmer; Mitchell F Roitman; Matthew R Hayes
Journal:  Neuropsychopharmacology       Date:  2014-07-18       Impact factor: 7.853

10.  Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.

Authors:  Matthew Riddle; Richard Pencek; Supoat Charenkavanich; Karen Lutz; Ken Wilhelm; Lisa Porter
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.